MiMedx Group Inc
NASDAQ: MDXG · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
MiMedx Group Inc (MDXG) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | — | $-16738.00 | — | — | — |
| 2007 | — | $-38860.00 | — | — | — |
| 2008 | — | $-17.37M | — | — | — |
| 2009 | — | $-11.92M | — | — | — |
| 2010 | $788874.00 | $-11.42M | -118.04% | -1,335.15% | -1,447.60% |
| 2011 | $7.76M | $-10.19M | 59.35% | -125.78% | -131.36% |
| 2012 | $27.05M | $-7.66M | 80.82% | -7.36% | -28.32% |
| 2013 | $59.18M | $-4.11M | 84.24% | -4.46% | -6.95% |
| 2014 | $118.22M | $6.22M | 89.29% | 6.01% | 5.26% |
| 2015 | $187.30M | $29.45M | 89.21% | 13.01% | 15.72% |
| 2016 | $245.01M | $11.97M | 86.77% | 0.36% | 4.89% |
| 2017 | $321.14M | $64.73M | 89.03% | 14.39% | 20.16% |
| 2018 | $359.11M | $-29.98M | 89.87% | -1.09% | -8.35% |
| 2019 | $359.11M | $-29.98M | 89.87% | -1.09% | -8.35% |
| 2020 | $248.23M | $-49.28M | 84.16% | -18.29% | -19.85% |
| 2021 | $242.02M | $-12.30M | 83.63% | -2.91% | -5.08% |
| 2022 | $267.84M | $-30.20M | 81.96% | -5.50% | -11.27% |
| 2023 | $321.48M | $67.44M | 83.01% | 11.55% | 20.98% |
| 2024 | $348.88M | $42.42M | 82.78% | 16.87% | 12.16% |
| 2025 | $418.63M | $48.58M | 82.56% | 15.26% | 11.60% |
Frequently asked questions
What is MiMedx Group Inc's revenue?
MiMedx Group Inc's trailing twelve-month revenue is $389.42M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is MDXG?
In its most recent fiscal year, MDXG ran a gross margin of 82.56%, an operating margin of 15.26%, and a net margin of 11.60%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does MDXG generate?
MDXG produced $72.97M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is MDXG's balance sheet healthy?
MDXG holds $166.12M in cash and equivalents against $16.47M in long-term debt, on $256.55M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.